In the claims:

The following listing of the claims replaces all prior versions and listings of the claims in the application.

1-2. (Canceled).

3. (Withdrawn) A vaccine comprising a polypeptide encoded by a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.

4. (Withdrawn) The vaccine of claim 3, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.

5. (Withdrawn) The vaccine of claim 3, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.

6. (Withdrawn) The vaccine of claim 5, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No. 25.

7. (Withdrawn) The vaccine of claim 5, wherein the nucleotide sequence is SEQ ID No. 25.

8. (Withdrawn) The vaccine of claim 3, wherein the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No. 26.

9. (Withdrawn) The vaccine of claim 8, wherein the polypeptide has the amino acid sequence of SEQ ID No. 26.

10. (Withdrawn) The vaccine of claim 3, wherein the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No. 26.

11. (Withdrawn) The vaccine of claim 10, wherein the homologue has at least 80% sequence identity to SEQ ID No. 26.

12. (Withdrawn) The vaccine of claim 3, wherein the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32.

13. (Withdrawn) A vaccine comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

14. (Withdrawn) A vaccine according to claim 13, further comprising a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.

15. (Withdrawn) A vaccine comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

16. (Withdrawn) A vaccine comprising a pharmaceutically acceptable vehicle and a single polypetide, wherein the single polypeptide consists of SEQ ID No. 26.

17. (Currently Amended) A vaccine comprising **[[a]]** **an isolated** nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, **wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25**.

18. (Previously Presented) A vaccine according to claim 17, wherein said nucleotide sequence is SEQ ID No. 15.

19. (Previously Presented) A vaccine according to claim 17, further comprising an adjuvant.

20. (Previously Presented) A vaccine according to claim 17, wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.

21. (Previously Presented) A vaccine of claim 20, further comprising an adjuvant.

22. (Previously Presented) A vaccine according to claim 21, wherein said nucleotide sequence is SEQ ID No. 15.

23. (Currently Amended) A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises **[[a]]** **an isolated** nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus**, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25**.

24. (Previously Presented) A method according to claim 23, wherein said nucleotide sequence is SEQ ID No. 15.

25. (Previously Presented) A method according to claim 23, wherein said vaccine further comprises an adjuvant.

26. (Previously Presented) A method according to claim 23, wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.

27. (Previously Presented) A method according to claim 26, wherein said vaccine further comprises an adjuvant.

28. (Previously Presented) A method according to claim 27, wherein said nucleotide sequence is SEQ ID No. 15.

29. (New) A vaccine comprising, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.

30. (New) A vaccine according to claim 29, wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.

31. (New) A vaccine according to claim 29, wherein said nucleotide sequence consists essentially of SEQ ID No. 15.

32. (New) A vaccine according to claim 29, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.

33. (New) A vaccine according to claim 29, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.

34. (New) A vaccine according to claim 33, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

35. (New) A vaccine according to claim 33, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

36. (New) A vaccine according to claim 32, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

37. (New) A vaccine according to claim 32, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

38. (New) A vaccine according to claim 29, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

39. (New) A vaccine according to claim 29, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

40. (New) A vaccine according to claim 29, wherein said nucleotide sequence consists of SEQ ID No. 15.

41. (New) A vaccine comprising, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response

effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.

42. (New) A vaccine according to claim 41, wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.

43. (New) A vaccine according to claim 41, wherein said nucleotide sequence consists essentially of SEQ ID No. 15.

44. (New) A vaccine according to claim 41, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.

45. (New) A vaccine according to claim 41, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.

46. (New) A vaccine according to claim 45, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

47. (New) A vaccine according to claim 45, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

48. (New) A vaccine according to claim 44, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

49. (New) A vaccine according to claim 44, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

50. (New) A vaccine according to claim 41, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

51. (New) A vaccine according to claim 41, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

52. (New) A vaccine comprising a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle,

wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said vaccine does not comprise naturally occurring porcine circovirus.

53. (New) A vaccine according to claim 52, wherein said nucleotide sequence is SEQ ID No. 15.

54. (New) A vaccine according to claim 52, further comprising an adjuvant.

55. (New) A vaccine according to claim 52, wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.

56. (New) A vaccine of claim 55, further comprising an adjuvant.

57. (New) A vaccine according to claim 56, wherein said nucleotide sequence is SEQ ID No. 15.

58. (New) A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said vaccine does not comprise naturally occurring porcine circovirus.

59. (New) A method according to claim 58, wherein said nucleotide sequence is SEQ ID No. 15.

60. (New) A method according to claim 58, further comprising an adjuvant.

61. (New) A method according to claim 58, wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.

62. (New) A method of claim 61, further comprising an adjuvant.

63. (New) A method according to claim 62, wherein said nucleotide sequence is SEQ ID No. 15.

64. (New) A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.

65. (New) A method according to claim 64, wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.

66. (New) A method according to claim 64, wherein said nucleotide sequence consists essentially of SEQ ID No. 15.

67. (New) A method according to claim 64, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.

68. (New) A method according to claim 64, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.

69. (New) A method according to claim 68, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

70. (New) A method according to claim 68, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

71. (New) A method according to claim 67, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

72. (New) A method according to claim 67, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

73. (New) A method according to claim 64, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

74. (New) A method according to claim 64, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

75. (New) A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 or SEQ ID No. 25.

76. (New) A method according to claim 75, wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.

77. (New) A method according to claim 75, wherein said nucleotide sequence consists essentially of SEQ ID No. 15.

78. (New) A method according to claim 75, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.

79. (New) A method according to claim 75, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.

80. (New) A method according to claim 79, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

81. (New) A method according to claim 79, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

82. (New) A method according to claim 78, wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

83. (New) A method according to claim 78, wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

84. (New) A method according to claim 75, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.

85. (New) A method according to claim 75, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.

86. (New) A method according to claim 75, wherein said nucleotide sequence consists of SEQ ID No. 15.